In March, the FDA slapped a partial clinical hold on the biotech's HIV program and a full clinical hold on its COVID-19 program for the same drug. At the time, the company sought out partners to rescue key programs, but to no avail.
Every year is a new failure. I've seen over the years too many penny stocks that claim a cure for whatever the latest concern was, from Bird Flu to Moon Rocks.